New eczema cream shows promise in tiny trial
NCT ID NCT06923228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested a new ointment called CGB-500 (containing tofacitinib) against an approved cream (ruxolitinib) for atopic dermatitis, a type of eczema. Only 3 people aged 12 and older took part, applying both treatments to different skin areas twice daily for 4 weeks. The goal was to see if CGB-500 reduces eczema severity and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib ointment (CGB-500)
- What this could lead to
- If it works, this could point toward a new topical treatment option for atopic dermatitis that is as effective as existing creams.
- What could go wrong
- This is a very small early-phase trial with only 3 participants, so results may not apply to the broader population. The drug may not prove more effective than the comparator or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Dermatology Clinical Research
Fremont, California, 94538, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease